Evidence map›Paper›PMID 35158972›Full record

ArticleCancers2022

Long-Term Outcome in a Phase II Study of Regional Hyperthermia Added to Preoperative Radiochemotherapy in Locally Advanced and Recurrent Rectal Adenocarcinomas.

Baard-Christian Schem, Frank Pfeffer, Martin Anton Ott, Johan N Wiig, Nils Sletteskog, Torbjørn Frøystein, Mette Pernille Myklebust, Sabine Leh, Olav Dahl, Olav Mella

Abstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Ten-year survival and pattern of recurrence in patients with locally recurrent rectal or sigmoid cancer undergoing resection.Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland · 2024
    Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Baard-Christian SchemThe Western Norway Regional Health Authority, 4034 Stavanger, Norway.
Frank PfefferDepartment of Gastrointestinal Surgery, Haukeland University Hospital and Institute of Clinical Medicine, Medical Faculty, University of Bergen, 5021 Bergen, Norway.
Martin Anton OttDepartment of Surgery, Haugesund Hospital, Helse Fonna, 5504 Haugesund, Norway.
Johan N WiigDepartment of Gastroenterological Surgery, Section of Surgical Oncology, Norwegian Radium Hospital, Oslo University Hospital HF, 0424 Oslo, Norway.
Nils SletteskogDepartment of Surgery, Førde Central Hospital, 6807 Førde, Norway.
Torbjørn FrøysteinDepartment of Oncology and Medical Physics, Haukeland University Hospital, 5021 Bergen, Norway.
Mette Pernille MyklebustDepartment of Oncology and Medical Physics, Haukeland University Hospital, 5021 Bergen, Norway.
Sabine LehDepartment of Pathology, Haukeland University Hospital and Institute of Clinical Medicine, Medical Faculty, University of Bergen, 5021 Bergen, Norway.ORCID 0000-0002-0764-2941
Olav DahlDepartment of Oncology and Medical Physics, Haukeland University Hospital, 5021 Bergen, Norway.
Olav MellaDepartment of Oncology and Medical Physics, Haukeland University Hospital, 5021 Bergen, Norway.

Funding

Trond Mohn Foundation BFS2015PAR02
6 · The paper itself

Abstract

Hyperthermia was added to standard preoperative chemoradiation for rectal adenocarcinomas in a phase II study. Patients with T3-4 N0-2 M0 rectal cancer or local recurrences were included. Radiation dose was 54 Gy combined with capecitabine 825 mg/m

Indexed as

chemoradiotherapyhyperthermiarectal cancertumour control

Identifiers

PMID35158972
PMCPMC8833356

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.